Alzamend Neuro, Inc.

NASDAQ:ALZN

2.32 (USD) • At close September 5, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2025202420232022202120202019201820172016
Revenue 0000000000
Cost of Revenue 0.051000000000
Gross Profit -0.051-0.051-0.0230000000
Gross Profit Ratio 0000000000
Reseach & Development Expenses 1.4156.4557.4465.2011.3111.0693.70.3230.2750
General & Administrative Expenses 03.4836.6827.1183.6413.3551.3090.5450.9430.069
Selling & Marketing Expenses 000.74300000.030.3310
SG&A 3.0313.4837.4257.1183.6413.3551.3090.5751.2730.069
Other Expenses 0000000000
Operating Expenses 4.4469.93814.8712.324.9524.4245.0090.8981.5480.069
Operating Income -4.497-9.938-14.87-12.32-4.952-4.424-5.009-0.898-1.548-0.069
Operating Income Ratio 0000000000
Total Other Income Expenses Net -0.018-0.01-0.008-0.043-0.0950.0140.146-0.033-0.0220
Income Before Tax -4.515-9.948-14.878-12.362-5.047-4.41-4.862-0.932-1.57-0.069
Income Before Tax Ratio 0000000000
Income Tax Expense 00-0.1450.0430-0.0140000
Net Income -4.515-9.948-14.878-12.362-5.047-4.41-4.862-0.932-1.57-0.069
Net Income Ratio 0000000000
EPS -11.32-14.72-2.25-20.92-0.89-9.26-12.4-1.64-8.18-0.42
EPS Diluted -11.32-14.7-2.25-2.1-0.89-9.25-12.4-1.64-8.18-0.42
EBITDA -4.446-9.887-14.847-12.316-4.95-4.41-5.0090.007-0.0220
EBITDA Ratio 0000000000